TY - JOUR
T1 - Feasibility of sentinel lymph node mapping of the ovary
T2 - a systematic review
AU - Dell'Orto, Federica
AU - Laven, Pim
AU - Delle Marchette, Martina
AU - Lambrechts, Sandrina
AU - Kruitwagen, Roy
AU - Buda, Alessandro
N1 - Publisher Copyright:
© IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2019/9
Y1 - 2019/9
N2 - Pelvic and para-aortic lymphadenectomy is routinely performed in early ovarian cancer to define the stage of the disease. However, it may be associated with increased blood loss, operative time, and length of hospitalization. The sentinel lymph node technique has been shown to be safe and feasible in vulvar, uterine, and cervical cancer. Data detailing feasibility and outcomes of sentinel lymph node mapping in ovarian cancer are scarce. To summarize the studies evaluating the feasibility of sentinel lymph node detection from the ovary, examining the technique and detection rate. A systematic search of the literature was performed using PubMed and Embase from June 1991 to February 2019. Studies describing the sentinel lymph node technique and lymphatic drainage of the ovaries were incorporated in this review. Ten articles were selected, comprising a total of 145 patients. A variety of agents were used, but the primary markers were technetium-99m radiocolloid (Tc-99m), patent blue, or indocyanine green, and the most common injection site was the ovarian ligaments. The overall sentinel lymph node detection rate was 90.3%. We propose a standardized technique sentinel lymph node mapping in ovarian cancer, using indocyanine green, or Tc-99m and blue dye as alternative tracers, injected in both the suspensory and the infundibulopelvic ligament of the ovary.
AB - Pelvic and para-aortic lymphadenectomy is routinely performed in early ovarian cancer to define the stage of the disease. However, it may be associated with increased blood loss, operative time, and length of hospitalization. The sentinel lymph node technique has been shown to be safe and feasible in vulvar, uterine, and cervical cancer. Data detailing feasibility and outcomes of sentinel lymph node mapping in ovarian cancer are scarce. To summarize the studies evaluating the feasibility of sentinel lymph node detection from the ovary, examining the technique and detection rate. A systematic search of the literature was performed using PubMed and Embase from June 1991 to February 2019. Studies describing the sentinel lymph node technique and lymphatic drainage of the ovaries were incorporated in this review. Ten articles were selected, comprising a total of 145 patients. A variety of agents were used, but the primary markers were technetium-99m radiocolloid (Tc-99m), patent blue, or indocyanine green, and the most common injection site was the ovarian ligaments. The overall sentinel lymph node detection rate was 90.3%. We propose a standardized technique sentinel lymph node mapping in ovarian cancer, using indocyanine green, or Tc-99m and blue dye as alternative tracers, injected in both the suspensory and the infundibulopelvic ligament of the ovary.
KW - ovarian cancer
KW - sentinel lymph node
KW - ENDOMETRIAL CANCER
KW - LYMPHADENECTOMY
KW - METASTASIS
KW - IDENTIFICATION
KW - MULTICENTER
KW - CARCINOMA
KW - BIOPSY
KW - TRIAL
U2 - 10.1136/ijgc-2019-000606
DO - 10.1136/ijgc-2019-000606
M3 - (Systematic) Review article
C2 - 31474589
SN - 1048-891X
VL - 29
SP - 1209
EP - 1215
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 7
ER -